Viridian Therapeutics reveals promising long-term results for veligrotug in treating thyroid eye disease, highlighting its ...

In THRIVE, Abrams' group recruited participants with moderate-to-severe active thyroid eye disease with proptosis at least 3 ...

IGF-1R is a clinically and commercially validated target for thyroid eye disease (TED) with U.S. revenues of approximately $2 billion in 2024. Veligrotug has the potential to improve patient ...

Christine Gustafson shares her story of living with Thyroid Eye Disease, where access to care and understanding often ...

Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company focused on discovering, developing, and commercializing potential best-in-class medicines for serious and rare diseases, today ...

A recent study from Bascom Palmer Eye Institute uncovered potential molecular evidence linking human papillomavirus (HPV) to ...

Veligrotug, also known as veli and VRDN-001, is an anti-insulin-like growth factor-1 receptor antibody delivered intravenously for thyroid eye disease (TED). Veli met the primary and secondary ...

Barraquer Eye Hospital UAE announces groundbreaking ... only FDA-approved medication specifically for Thyroid Eye Disease (TED). Thyroid Eye Disease is a rare, vision-threatening autoimmune ...

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) yesterday approved Tepezza (teprotumumab (Tepezza). This ...

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation for Amgen’s Tepezza ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved teprotumumab (Tepezza), the first medicine licensed ...